Company profile
BRIACELL THERAPEUTICS CORP.
NASDAQ:BCTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SV-BR-1-GM | phase3 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06471673 | phase1_2 | unknown | 2024-05-29 | 2025-04-30 | BriaCell Therapeutics Corporation | A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer |
| NCT03328026 | phase1_2 | completed | 2018-03-16 | 2026-03-24 | BriaCell Therapeutics Corporation | Combination Study of SV-BR-1-GM With Retifanlimab |
| NCT03066947 | phase1_2 | completed | 2017-05-05 | 2018-11-22 | BriaCell Therapeutics Corporation | SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer |
| NCT06072612 | phase3 | recruiting | 2023-12-05 | 2027-12-01 | BriaCell Therapeutics Corporation | Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. |
FDA applications (0)
No records yet.